Sarepta Therapeutics, Inc. faces a disastrous 2025, with Elevidys-linked patient deaths, halted shipments, and a >90% stock price collapse. SRPT implemented a major restructuring, slashing 36% of its ...
I am downgrading SRPT to 'Hold' due to platform-level safety concerns, management credibility issues, and ongoing regulatory scrutiny after multiple patient deaths. ELEVIDYS remains a commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results